Halofenate

Overview

Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Endocrinology | Products > Signaling Pathways > β-catenin | Products > Signaling Pathways > Wnt | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-14998
• CAS No.: 26718-25-2
• Molecular Formula: C19H17ClF3NO4
• Molecular Weight: 415.79
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source